The aim of this study was to evaluate the predictive impact of defined IDH mutational subgroups on outcome of alloHCT in first complete remission (CR1) after intensive induction therapy in a well-defined, large multi-center cohort of IDHmut AML patients. The gene discussed is IDH1; the disease is acute myeloid leukemia.